Current Medical Management of Secondary Hyperparathyroidism

Yudd, Michael; Llach, Francisco

doi:10.1097/00000441-200008000-00007

Cited by 27 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…End-stage renal disease has not universally been considered a high-risk condition for valvular heart disease, and the magnitude of the risk was not previously known. However, increased risk is not unexpected due to the high prevalence of hyperparathyroidism in this population [18], which has been linked with cardiac abnormalities in patients with chronic renal failure [19, 20, 21, 22]. Not unexpectedly, dialysis modality (hemodialysis vs. peritoneal dialysis) was not a risk factor in the present analysis.…”

Section: Discussionmentioning

confidence: 58%

Hospitalizations for Valvular Heart Disease in Chronic Dialysis Patients in the United States

Abbott¹,

Agodoa²

2002

Nephron

View full text Add to dashboard Cite

Background: Valvular heart disease has not been studied in a national population of end stage renal disease patients. Methods: 327,993 dialysis patients in the United States Renal Data System initiated from 1 January 1992 to 30 June 1997 were analyzed in a historical cohort study of patients hospitalized for valvular heart disease (ICD9 Code 424.x, excluding endocarditis, and 394.x-397.x). Results: 2,778 dialysis patients were hospitalized for VHD (incidence rate, 3.57 per 1,000 person years), and dialysis patients had an age-adjusted incidence ratio for valvular heart disease of 5.06 (95% confidence interval, 4.00–6.42) compared to the general population in 1996. In Cox regression analysis, time to hospitalization for valvular heart disease was associated with earlier year of first dialysis, increased age, congestive heart failure and use of erythropoietin prior to dialysis, while African-American race (AHR 0.62, 0.52–0.74) was associated with decreased risk of hospitalization for valvular heart disease. Patients hospitalized for valvular heart disease had increased mortality compared to all other dialysis patients (adjusted hazard ratio by Cox regression 1.35, 95% CI, 1.25–1.46). Conclusions: Dialysis patients were at increased risk for hospitalizations for valvular heart disease compared to the general population, which substantially decreased patient survival. The reasons for the decreased risk of African-Americans on chronic dialysis for this complication should be the subject of future trials.

show abstract

Section: Discussionmentioning

confidence: 58%

Hospitalizations for Valvular Heart Disease in Chronic Dialysis Patients in the United States

Abbott¹,

Agodoa²

2002

Nephron

View full text Add to dashboard Cite

show abstract

“…These include the control of hyperphosphatemia, the maintenance of normocalcemia, and the administra- 11 Our patient did not show any symptoms associated with hyperparathyroidism, such as skeletal pain, disabling fractures, tendon ruptures, pruritus, and so on. At present, parathyroidectomy is not indicated.…”

Section: Report Of a Casementioning

confidence: 65%

A Case of Ectopic Parathyroid Gland Hyperplasia in the Pyriform Sinus

Fukumoto

Nonaka²,

Kamio³

et al. 2002

Arch Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Variability in the location of parathyroid glands is well recognized. There are usually 4 parathyroid glands located in the area of the thyroid gland, but embryologically, they may be found anywhere from the angle of the jaw to the pericardium. We report a case of an ectopic parathyroid gland in the pyriform sinus. It appeared as a tumorous lesion in the pyriform sinus owing to progress of secondary hyperparathyroidism.

show abstract

“…Intestinal phosphate‐binding agents may be useful to further reduce phosphate retention and hyperparathyroidism in these dogs. High dietary phosphorus, however, may greatly limit the effectiveness of phosphate‐binding agents and substantially increase the dose required to achieve the desired therapeutic effect (Yudd and Llach 2000). In a study of dogs with moderate CKD, administration of aluminium carbonate failed to consistently correct hyperphosphataemia when dogs consumed foods containing more than 1·0% phosphorus on a dry matter basis (Finco and others 1985).…”

Section: Nutritional Management Of Ckdmentioning

confidence: 99%

An evidence‐based review of therapies for canine chronic kidney disease

Roudebush

Polzin

Adams³

et al. 2010

J of Small Animal Practice

View full text Add to dashboard Cite

Successful treatment and prevention of kidney disease in dogs requires a multi-dimensional approach to identify and eliminate causes or exacerbating factors, provide professional evaluation on a regular basis and implement a comprehensive treatment programme when necessary. Over the years, many therapeutic and preventive interventions have been developed or advocated for chronic kidney disease in dogs, but evidence of efficacy or effectiveness is often lacking or highly variable. Accordingly, the main objective of this systematic review was to identify and critically appraise the evidence supporting various aspects of managing canine chronic kidney disease.

show abstract

Current Medical Management of Secondary Hyperparathyroidism

Cited by 27 publications

References 27 publications

Hospitalizations for Valvular Heart Disease in Chronic Dialysis Patients in the United States

Hospitalizations for Valvular Heart Disease in Chronic Dialysis Patients in the United States

A Case of Ectopic Parathyroid Gland Hyperplasia in the Pyriform Sinus

An evidence‐based review of therapies for canine chronic kidney disease

Contact Info

Product

Resources

About